Traws Pharma Reports Zero Revenue and $3.05 Million Net Loss for Q2 2026

Traws Pharma, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded no revenue for the quarter, a stark decline from $2.7 million in the same period last year. For the first half of 2026, Traws Pharma also reported zero revenue, down from $2.79 million in the first half of 2025. The absence of revenue is attributed to the termination of a licensing agreement with Symbio Pharmaceuticals in April 2025, which had previously contributed to the company's income.

Operating expenses for the second quarter of 2026 totaled $3.18 million, a decrease from $3.98 million in the prior year. This reduction was primarily driven by a 52% decrease in research and development expenses, which fell to $1.1 million from $2.3 million, reflecting lower spending on the tivoxavir marboxil program. However, general and administrative expenses surged by 106% to $3.48 million, largely due to increased professional fees and stock-based compensation. The net loss for the quarter was $3.05 million, compared to a loss of $915,000 in the same quarter of 2025.

In terms of strategic developments, Traws Pharma underwent a significant merger with Trawsfynydd Therapeutics in April 2024, which expanded its clinical program portfolio to include four investigational therapies targeting respiratory viral diseases and cancer. The company is focusing on advancing its lead candidates, tivoxavir marboxil and ratutrelvir, but has faced regulatory hurdles, including a clinical hold from the FDA on tivoxavir marboxil due to concerns regarding its toxicology data. The company is actively working to address these issues and plans to resubmit an updated data package to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a human challenge trial.

As of June 30, 2026, Traws Pharma reported cash and cash equivalents of $5.02 million, an increase from $3.82 million at the end of 2025. However, the company has an accumulated deficit of approximately $650.1 million and anticipates that its existing cash will not be sufficient to fund operations for the next 12 months. Traws Pharma is exploring various financing options, including equity financings and strategic partnerships, to support its ongoing clinical trials and operations. The company has expressed substantial doubt about its ability to continue as a going concern if it cannot secure additional funding.

Looking ahead, Traws Pharma's management remains focused on advancing its clinical programs while navigating the challenges posed by regulatory requirements and funding needs. The company is committed to addressing the FDA's concerns regarding its investigational therapies and is actively seeking to establish partnerships that could facilitate the development and commercialization of its product candidates.